4 Best Small-Cap Synthetic Biology Stocks — May 2026
Synthetic biology as a public small-cap category is mostly the post-SPAC survivors. 4 names with very different business models — organism foundry, antibody engineering, drug-discovery software, and a misclassified med-device.
Synthetic biology had its post-SPAC rationalization in 2022-2024 — Amyris filed for bankruptcy, Ginkgo Bioworks downsized multiple times, and the broad 'synbio is the future' narrative gave way to harder questions about unit economics. The names that survived have very different business models, and what gets bundled as 'synbio' includes some companies that fit the label loosely.
We scored every small-cap with primary synthetic-biology, organism-engineering, or genomics-platform exposure. Here are 4 names that scored highest, with honest framing of which actually fit the synbio definition tightly.
Why Small-Cap Synthetic Biology Is Different
- 'Synbio' is a marketing label, not a business model — the category includes organism foundries (DNA), antibody engineering (ZYME), drug-discovery software (SDGR), and miscellaneous med-device names that get screened in.
- Cash burn is the unifying problem — pre-commercial-scale synbio operations are capex-heavy and revenue-light. Multi-year runway is the survivability metric.
- Customer concentration is structural — organism-foundry models depend on big pharma, ag, and biosecurity customers signing multi-million-dollar custom-strain contracts. One contract delay is material.
- IPO-era valuations broken — most of these names trade at 10-20% of their post-SPAC peak. The bull case requires both a recovery in unit economics and a mean-reversion in capital-markets sentiment.
Our scoring rewards balance-sheet quality, dilution discipline, and capital efficiency. For synbio names, runway-to-platform-monetization and gross-margin trajectory are the operative metrics.
Top 4 Small-Cap Synthetic Biology Stocks by Fundamental Score — May 2026
Get picks like these first.
Free weekly digest — top movers, score changes, new small-cap opportunities. No spam, unsubscribe anytime.
1. Sanara MedTech Inc. (SMTI) — Score: 77.8 | Grade: SOLID
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +33.4% | 53 |
| Gross Margin | 90.6% | 100 |
| Cash Runway | >36 months | 100 |
| Debt/Equity | 81.93 | 26 |
| P/S Ratio | 1.7x | 96 |
| Rule of 40 | 23.4 | 55 |
| Insider Ownership | 65.3% | 100 |
| 12m Dilution | +2.1% | 88 |
What drives the score: Sanara MedTech sells wound-care and surgical biologics. Not synbio per se, but listed in adjacent category by some screens. Rapid revenue growth through specialty-hospital channel, profitable on contribution margin.
Key risk: Wound-care biologics is technically not synthetic biology. Listed here only because some screens classify wound-care biologics under synbio adjacency. Real business is specialty-hospital channel sales, similar to other med-device names.
Market cap: $175M. Industry: Medical Instruments & Supplies.
2. Schrodinger, Inc. (SDGR) — Score: 62.4 | Grade: SOLID
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +23.3% | 37 |
| Gross Margin | 55.7% | 79 |
| Cash Runway | >36 months | 100 |
| Debt/Equity | 30.00 | 75 |
| P/S Ratio | 3.7x | 83 |
| Rule of 40 | -41.9 | 0 |
| Insider Ownership | 2.9% | 23 |
| 12m Dilution | -11.8% | 100 |
What drives the score: Schrödinger is the longest-running physics-based molecular-simulation software vendor for drug discovery (Glide, FEP+, Maestro). Software segment sold to most large pharmas and is gross-margin positive; internal drug-development pipeline drives the corporate-level losses.
Key risk: Software-segment growth deceleration would re-rate the multiple. Drug-pipeline programs are early; corporate-level losses are funded by software cash flow. Strategic clarity on capital allocation between software franchise growth and drug development is the open question.
Market cap: $939M. Industry: Health Information Services.
3. Ginkgo Bioworks Holdings, Inc. (DNA) — Score: 41.9 | Grade: SPECULATIVE
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | -25.1% | 0 |
| Gross Margin | 72.4% | 100 |
| Cash Runway | 12 months | 39 |
| Debt/Equity | 86.49 | 22 |
| P/S Ratio | 2.5x | 93 |
| Rule of 40 | -203.6 | 0 |
| Insider Ownership | 3.4% | 27 |
| 12m Dilution | -8.7% | 100 |
What drives the score: Ginkgo Bioworks operates an organism-foundry platform — designs and produces engineered microbes for pharma, agriculture, biosecurity. Multiple downsizing rounds in 2023-2024; strategic question is whether the foundry model produces enough recurring economics to fund itself.
Key risk: Multiple downsizing rounds in 2023-2024 reflect the gap between platform promise and revenue delivery. Cell-engineering services pricing is under pressure from in-house pharma capabilities. Strategic question: is the foundry model sustainable, or is it a service-business with platform-business pricing expectations.
Market cap: $424M. Industry: Biotechnology.
Still reading? Get the full weekly rundown.
Every Monday: fresh score changes, new names crossing 80+, and context you won't find in the screener.
4. Zymeworks Inc. (ZYME) — Score: 38.4 | Grade: HIGH RISK
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +38.9% | 62 |
| Gross Margin | N/A | 0 |
| Cash Runway | 15 months | 52 |
| Debt/Equity | 6.80 | 95 |
| P/S Ratio | 17.6x | 18 |
| Rule of 40 | -48.5 | 0 |
| Insider Ownership | 1.3% | 10 |
| 12m Dilution | +6.0% | 64 |
What drives the score: Zymeworks designs bispecific antibodies and antibody-drug conjugates. Multiple programs licensed to BeiGene, Daiichi Sankyo, others — milestone revenue + royalty stream once launched. Wholly-owned lead ZW171 (HER2-bispecific) is in early trials.
Key risk: Bispecific antibody and ADC programs are partner-heavy (BeiGene, Daiichi Sankyo). Milestone payments are lumpy; royalty stream begins once partner programs reach commercial sales (multi-year horizon). Wholly-owned ZW171 in early trials adds option value but also dilution risk.
Market cap: $1.87B. Industry: Biotechnology.
What these 4 stocks have in common
-
The 'synbio' tag is loose at the small-cap level. DNA fits tightly. ZYME fits loosely (engineered antibodies). SDGR fits as 'in-silico biology' rather than wet-lab synbio. SMTI fits only as adjacent.
-
Cash position is the survival variable. Each name's runway dictates which can survive multiple platform-validation cycles vs. which need to monetize quickly.
-
Big pharma is the customer or partner for three of four. Customer concentration is real; partnership-deal news flow drives much of the equity volatility.
What's not on this list — and why
- Twist Bioscience (TWST) — sub-$1B market cap typical, oligonucleotide and synthetic-DNA writing. We do not currently have TWST in our scored universe; readers interested in synbio exposure should look at it independently.
- Codexis (CDXS) — small-cap, enzyme engineering; in restructuring through 2025.
- Berkeley Lights / IsoPlexis / Element Biosciences — most have either delisted, merged, or substantially impaired through 2024.
- Mammoth Biosciences, Synthego, Asimov — private; key synbio names not available to public investors.
- Amyris — filed Chapter 11 in 2023; cautionary tale for SPAC-era synbio exposure.
Public small-cap synbio is mostly the post-SPAC survivors. Investors looking for broader exposure typically find that the most credible names are private, and the public investable layer is narrower than the marketing of the category suggests. Position-sizing should reflect the high binary risk of remaining names.
How to use this data
These scores measure financial health, not platform credibility or partnership-pipeline depth. For synbio names:
- Watch quarterly cash burn and dilution-rate; multi-year survivability is the dominant variable
- For DNA, downsizing-round announcements vs. revenue-trajectory updates indicate strategic momentum
- For ZYME, partner-program milestone announcements (especially BeiGene-related) drive lumpy revenue
- For SDGR, software-segment ARR growth is the metric to watch quarterly
SmallCapScanner scores are calculated algorithmically based on 8 fundamental factors. They measure financial health, not future performance. See /how-it-works for the full methodology.
Track these stocks and 2,200+ others on our screener. Set alerts to know when a score crosses your threshold, or compare two tickers directly on /compare.